Reduced hemodialysis adequacy after hemoglobin normalization with epoetin

Area of Science:

• Nephrology
• Hematology
• Internal Medicine

Background:

• Elevated hemoglobin (Hb) and blood viscosity can impair hemodialyzer clearance.
• Epoetin alfa treatment aims to normalize Hb levels in hemodialysis (HD) patients.
• The impact of normalized Hb on HD adequacy requires investigation.

Purpose of the Study:

• To evaluate hemodialysis (HD) adequacy after epoetin alfa treatment targeting normal Hb levels.
• To compare HD adequacy between patients with normalized Hb and those with subnormal Hb.
• To determine if increased dialysis doses are necessary for normalized Hb patients.

Main Methods:

• Thirty-three HD patients were randomized into two groups: normal Hb (135-160 g/L) and subnormal Hb (90-120 g/L).
• Epoetin alfa was administered to achieve target Hb levels.
• Hemodialysis adequacy was assessed using single-pool Kt/V measurements.

Main Results:

• In the normal Hb group (n=10), Hb reached 144 +/- 11 g/L; in the subnormal group (n=14), Hb was 109 +/- 10 g/L.
• Single-pool Kt/V decreased significantly (p<0.01) from 1.25 to 1.15 in the normal Hb group.
• Kt/V remained constant in the subnormal Hb group (1.26).

Conclusions:

• Normalization of Hb with epoetin alfa in HD patients led to a statistically significant reduction in Kt/V.
• This suggests that current dialysis doses may be insufficient to maintain adequacy when Hb is normalized.
• An increased dialysis dose might be required to compensate for reduced hemodialyzer clearance in patients with normalized Hb.